Autism Spectrum Disorder Trial, Recruiting (NCT05590715)

Autism Spectrum Disorder Trial, Recruiting NCT05590715 Sponsor: Stalicla SA Condition: Autism Spectrum Disorder

Printed from Voxsanity (voxsanity.com.au) — NCT05590715 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Autism Spectrum Disorder

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have previously been diagnosed with Autism Spectrum Disorder (ASD) according to standard diagnostic guidelines (DSM-5)
People who have well-documented health records from the first two years of their life available
People who have a parent or reliable caregiver who is willing to provide information about them
People who are willing to take part and have given their agreement (or assent) to participate

Who may not be able to join:

People who have had a fever (100.5°F / 38°C or higher) or a significant illness without fever within the 10 days before any study assessment, as assessed by the trial investigator
People where the trial investigator identifies any unwillingness to participate or any medical condition that could prevent them from completing the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Paulo Fontoura, MD, PhD, Stalicla SA

Phone: +41 22 545 12 42

Australian sites

Children's Health Queensland Hospital and Health Service, South Brisbane, Queensland

Mater Misericordiae Limited, South Brisbane, Queensland

Flinders Medical Centre, Bedford Park, South Australia

Locuspsych, Melbourne, Victoria

Murdoch Children's Research Institute, Parkville, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05590715

Sponsor: Stalicla SA

Phase: Not Applicable

Status: Recruiting

Condition: Autism Spectrum Disorder

Trial contact: +41 22 545 12 42

More information: https://clinicaltrials.gov/study/NCT05590715

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have previously been diagnosed with Autism Spectrum Disorder (ASD) according to standard diagnostic guidelines (DSM-5)
People who have well-documented health records from the first two years of their life available
People who have a parent or reliable caregiver who is willing to provide information about them
People who are willing to take part and have given their agreement (or assent) to participate

Who may not be able to join:

People who have had a fever (100.5°F / 38°C or higher) or a significant illness without fever within the 10 days before any study assessment, as assessed by the trial investigator
People where the trial investigator identifies any unwillingness to participate or any medical condition that could prevent them from completing the study

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Stalicla SA

Registry

ClinicalTrials.gov

Start date

13 October 2022

Est. completion

31 March 2027

Where this trial is recruiting

🇦🇺 Australia 🇪🇸 Spain 🇺🇸 United States

5 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Clinical characterisation of the ASD-Phen1 and ASD-Phen2 subpopulations.; Molecular characterization of the ASD-Phen1 and ASD-Phen2 subpopulations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov